试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-03-12
Permeability MRI in Cerebral Cavernous Malformations Type 1 in New Mexico: Effects of Statins
编号:NCT01764451登记状态:提前终止企业 / 申办者:University of New Mexico
药物 / 成分:Simvastatin
登记的停止原因(原文):Research was completed before January 18, 2017, \& does not meet the Applicable Clinical Trial requirement to register \& report results per the guidance provided in "Clinical Trials Registration \& Results Information Submission" dated 09/21/2016.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-03-12
Basket Study of Neratinib in Participants With Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations
编号:NCT01953926登记状态:提前终止企业 / 申办者:Puma Biotechnology, Inc.
药物 / 成分:Neratinib、Fulvestrant、Trastuzumab、Paclitaxel
登记的停止原因(原文):The study was terminated to align with the sponsor's current development plans for neratinib. The decision was not based on any new efficacy or safety data for neratinib.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-03-12
Enhancing Anti--Tetanus Vaccine Response After Autologous Stem Cell Transplantation
编号:NCT02700841登记状态:提前终止企业 / 申办者:University of Nebraska
药物 / 成分:Melphalan、Peripheral Blood Stem Cell Transplantation--CD34 HSCT、Peripheral Blood Stem Cell Transplantation--AHSCT、T Cell-Depleted Hematopoietic Stem Cell Transplantation
登记的停止原因(原文):Study terminated prematurely due to poor recruitment.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-03-12
A Study of Acute Graft-Versus-Host Disease (GVHD) in Patients Undergoing Allogeneic Stem-Cell Transplantation
编号:NCT02737306登记状态:提前终止企业 / 申办者:CytoDyn, Inc.
药物 / 成分:PRO 140、Placebo
登记的停止原因(原文):Study terminated due to lack of enrolment..
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-03-12
Transarterial Chemoembolization Compared With Stereotactic Body Radiation Therapy or Stereotactic Ablative Radiation Therapy in Treating Patients With Residual or Recurrent Liver Cancer Undergone Initial Transarterial Chemoembolization
编号:NCT02762266登记状态:提前终止企业 / 申办者:Stanford University
药物 / 成分:Stereotactic Body Radiation Therapy、Transarterial Chemoembolization、embolic agent、lipiodol
登记的停止原因(原文):Business decision - funding
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-03-12
Idelalisib Post Allogeneic Hematopoietic Stem Cell Transplant (HSCT) in B Cell Derived Malignancies
编号:NCT03151057登记状态:提前终止企业 / 申办者:Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
药物 / 成分:Idelalisib 100 MG、Placebo Oral Tablet
登记的停止原因(原文):Safety endpointreached
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-03-12
Efficacy and Safety of Crinone Versus Combination Medication (ACCESS)
编号:NCT03858049登记状态:提前终止企业 / 申办者:Merck KGaA, Darmstadt, Germany
药物 / 成分:Crinone、Duphaston
登记的停止原因(原文):The trend in LPS treatment tends to increase the dosage of progesterone in FET-HRT, this study was designed 5 years ago.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-03-12
A Study of LY3154885 in Healthy Participants
编号:NCT04014361登记状态:提前终止企业 / 申办者:Eli Lilly and Company
药物 / 成分:LY3154885 - Capsule、Placebo - Capsule、Itraconazole、LY3154885 - Tablet
登记的停止原因(原文):HUAA study is terminated early due to a business decision.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-03-12
Phase 3 Trial of Pamrevlumab or Placebo With Systemic Corticosteroids in Participants With Non-ambulatory Duchenne Muscular Dystrophy (DMD)
编号:NCT04371666登记状态:提前终止企业 / 申办者:Kyntra Bio
药物 / 成分:Pamrevlumab、Placebo、Corticosteroids
登记的停止原因(原文):Study did not meet its primary endpoint.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-03-12
PTX-35 in Patients With Advanced Solid Tumors
编号:NCT04430348登记状态:提前终止企业 / 申办者:Pelican Therapeutics, Inc.
药物 / 成分:PTX-35
登记的停止原因(原文):Absence of immunological response
查看官方原始记录 ↗